Secord, A. A., Previs, R. A., Pothuri, B., Strickland, K. C., Gay, L., Levine, D. A., … Elvin, J. A. (2019). Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer. In Gynecologic Oncology (Vol. 154, pp. 248–248). Elsevier BV. https://doi.org/10.1016/j.ygyno.2019.04.572

Secord, A. A., R. A. Previs, B. Pothuri, K. C. Strickland, L. Gay, D. A. Levine, B. A. Davidson, and J. A. Elvin. “Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer.” In Gynecologic Oncology, 154:248–248. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.572.

Secord AA, Previs RA, Pothuri B, Strickland KC, Gay L, Levine DA, et al. Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer. In: Gynecologic Oncology. Elsevier BV; 2019. p. 248–248.

Secord, A. A., et al. “Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer.” Gynecologic Oncology, vol. 154, Elsevier BV, 2019, pp. 248–248. Crossref, doi:10.1016/j.ygyno.2019.04.572.

Secord AA, Previs RA, Pothuri B, Strickland KC, Gay L, Levine DA, Davidson BA, Elvin JA. Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer. Gynecologic Oncology. Elsevier BV; 2019. p. 248–248.